EL7.AI
StocksMediumUpdated•Originally published 11 March 2026•Updated 11 March 2026•
1 min read

Regenxbio Shares Slide Despite Positive Interim Data for Duchenne Gene Therapy

Key Facts

1RGX-202 gene therapy demonstrated evidence of positively changing the Duchenne disease trajectory in Phase I/II trials.
2Pivotal dose participants exceeded external controls across functional measures at one year post-treatment.
3No serious adverse events were observed, with stable cardiac MRI data and supported liver safety.
4Pivotal topline data is expected to be released in the second quarter of 2026.

REGENXBIO Inc. (Nasdaq: RGNX) shares declined on Wednesday following the release of interim data for its Duchenne muscular dystrophy therapy trial. The stock slide is attributed to mixed signals in the market that led to selling pressure, despite the positive clinical outcomes reported in the Phase I/II AFFINITY DUCHENNE trial for RGX-202. Clinical data indicated that participants in the pivotal dose group exceeded external controls in functional measures after one year of treatment. Safety remains a strong point, with no serious adverse events reported and stable cardiac MRI and liver safety profiles. While the progress positions RGX-202 as a potential best-in-class treatment, the market reaction reflects a cautious stance ahead of pivotal topline data expected in Q2 2026. This update highlights a disconnect between promising clinical milestones and immediate investor sentiment.